ARTICLE | Management Tracks
CMO Roberts to succeed Chang as Allogene CEO
Plus: FDA veteran Fashoyin-Aje lands at AZ and other biopharma management moves
May 30, 2026 12:22 AM UTC
Zachary Roberts will succeed David Chang as president and CEO of Allogene Therapeutics Inc. (NASDAQ:ALLO) on July 1. Roberts, who will also join the board, is EVP of R&D and CMO of the off-the-shelf cell therapy company. Chang, an Allogene co-founder who has led the company for the past eight years, will continue to serve on the board...